Ontology highlight
ABSTRACT:
PROVIDER: PRJEB22863 | ENA |
REPOSITORIES: ENA
Action | DRS | |||
---|---|---|---|---|
ERR2213660.fastq.gz | Fastqsanger.gz | |||
ERR2213670.fastq.gz | Fastqsanger.gz | |||
ERR2213680.fastq.gz | Fastqsanger.gz | |||
ERR2213690.fastq.gz | Fastqsanger.gz | |||
ERR2213700.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 5 of 219 |
Routy Bertrand B Le Chatelier Emmanuelle E Derosa Lisa L Duong Connie P M CPM Alou Maryam Tidjani MT Daillère Romain R Fluckiger Aurélie A Messaoudene Meriem M Rauber Conrad C Roberti Maria P MP Fidelle Marine M Flament Caroline C Poirier-Colame Vichnou V Opolon Paule P Klein Christophe C Iribarren Kristina K Mondragón Laura L Jacquelot Nicolas N Qu Bo B Ferrere Gladys G Clémenson Céline C Mezquita Laura L Masip Jordi Remon JR Naltet Charles C Brosseau Solenn S Kaderbhai Coureche C Richard Corentin C Rizvi Hira H Levenez Florence F Galleron Nathalie N Quinquis Benoit B Pons Nicolas N Ryffel Bernhard B Minard-Colin Véronique V Gonin Patrick P Soria Jean-Charles JC Deutsch Eric E Loriot Yohann Y Ghiringhelli François F Zalcman Gérard G Goldwasser François F Escudier Bernard B Hellmann Matthew D MD Eggermont Alexander A Raoult Didier D Albiges Laurence L Kroemer Guido G Zitvogel Laurence L
Science (New York, N.Y.) 20171102 6371
Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis induce sustained clinical responses in a sizable minority of cancer patients. We found that primary resistance to ICIs can be attributed to abnormal gut microbiome composition. Antibiotics inhibited the clinical benefit of ICIs in patients with advanced cancer. Fecal microbiota transplantation (FMT) from cancer patients who responded to ICIs into germ-free or antibiotic-treated mice ameliorated the antitumor effects of PD-1 blocka ...[more]